CAMBRIDGE, Mass. – An experimental, personalized mRNA treatment developed by Moderna and Merck reduced the risk of melanoma returning or spreading in a large Phase 3 study when it was added to the immunotherapy Keytruda, the companies announced.
The treatment, called intismeran autogene and previously known as mRNA-4157 or V940, is made separately for each patient. Scientists sequence a removed tumor, identify mutations that may be recognized by the immune system and create an mRNA therapy designed to train immune cells to attack cancer cells carrying those signals.
The INTerpath-001 trial enrolled more than 1,100 people with high-risk stage IIB through stage IV melanoma whose tumors had been completely removed by surgery. Participants received either intismeran with pembrolizumab, sold as Keytruda, or pembrolizumab alone as treatment intended to prevent recurrence.
Moderna and Merck said the combination produced a statistically significant and clinically meaningful improvement in recurrence-free survival, the study’s primary measure. It also met a key secondary goal by improving distant metastasis-free survival, which measures how long patients remain alive without cancer spreading to a distant organ or tissue.
The announcement was based on topline results. The companies did not release the actual survival rates, the size of the risk reduction or detailed safety findings, and they did not say whether the combination improved overall survival. They plan to present full results at a medical meeting and discuss the data with regulatory agencies.
Those missing details matter when doctors judge whether a treatment’s benefits outweigh its risks and costs. A successful trial does not make the therapy immediately available. Intismeran remains investigational and has not been approved by the U.S. Food and Drug Administration.
Keytruda is a checkpoint inhibitor that blocks the PD-1 pathway, which tumors can use to evade immune attack. The personalized mRNA component is designed to give the immune system a patient-specific list of tumor targets, while Keytruda helps immune cells remain active against those targets.
Earlier randomized Phase 2b results in patients with resected high-risk stage III or IV melanoma showed a sustained recurrence-free-survival benefit after five years of follow-up. The larger Phase 3 study was needed to confirm whether the finding held in a broader population and against the current standard treatment.
The trial is also an important test of mRNA technology beyond infectious-disease vaccines. Moderna and Merck are studying personalized neoantigen therapies in melanoma, lung, bladder and kidney cancers, but a result in one cancer and treatment setting does not establish effectiveness in another.
Patients with melanoma should not change treatment based on a company announcement. Surgery, immunotherapy, targeted drugs and clinical trials are selected according to cancer stage, tumor characteristics and individual health. An oncologist can explain approved options and whether a research study is appropriate.
Source: Gizmodo, published Aug. 20, 2026. Additional verification: Moderna’s Aug. 19, 2026, Phase 3 announcement, Merck clinical updates and ClinicalTrials.gov.
